Global Markets Direct's latest Pharmaceutical and
Healthcare disease pipeline guide Acute Lymphocytic Leukemia - Pipeline Review,
H1 2018, provides an overview of the Acute
Lymphocytic Leukemia (Oncology) pipeline landscape.
Acute
lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the
production of a large number of immature lymphocytes thus blocking the
production of normal blood cells. It enters the blood stream and rapidly progress
to other parts of the body such as spleen, lymph nodes and liver. Risk factors
for ALL include exposure to radiation or chemicals, age, virus infections and
genetic factors. Symptoms include anemia, frequent infections, easy bruising,
bone pain and breathing problems. Treatment includes chemotherapy,
transfusions, transplant and medications.
Global Markets Direct's Pharmaceutical and
Healthcare latest pipeline guide Acute Lymphocytic Leukemia - Pipeline Review,
H1 2018, provides comprehensive information on the therapeutics under
development for Acute Lymphocytic Leukemia (Oncology), complete with analysis
by stage of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive pharmacological
action of the therapeutics, its complete research and development history and
latest news and press releases.
The
Acute Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key
players involved in therapeutic development for Acute Lymphocytic Leukemia
(ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued
projects. The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in
Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and
Discovery stages are 5, 3, 58, 52, 2, 69 and 5 respectively. Similarly, the
Universities portfolio in Phase III, Phase II, Phase I, Preclinical, Discovery
and Unknown stages comprises 1, 15, 19, 13, 3 and 1 molecules, respectively.
Acute
Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to gain
competitive advantage. The guide is built using data and information sourced
from Global Markets Direct's proprietary databases, company/university
websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic tracking
processes ensure that the most recent developments are captured on a real time
basis.
- The pipeline guide provides a snapshot of the
global therapeutic landscape of Acute Lymphocytic Leukemia (Oncology).
-
The pipeline guide reviews pipeline therapeutics for Acute Lymphocytic Leukemia
(Oncology) by companies and universities/research institutes based on
information derived from company and industry-specific sources.
-
The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and undisclosed
stages.
-
The pipeline guide features descriptive drug profiles for the pipeline products
which comprise, product description, descriptive licensing and collaboration
details, R&D brief, MoA & other developmental activities.
-
The pipeline guide reviews key companies involved in Acute Lymphocytic Leukemia
(Oncology) therapeutics and enlists all their major and minor projects.
-
The pipeline guide evaluates Acute Lymphocytic Leukemia (Oncology) therapeutics
based on mechanism of action (MoA), drug target, route of administration (RoA)
and molecule type.
-
The pipeline guide encapsulates all the dormant and discontinued pipeline
projects.
-
The pipeline guide reviews latest news related to pipeline therapeutics for
Acute Lymphocytic Leukemia (Oncology)
- Procure strategically important competitor
information, analysis, and insights to formulate effective R&D strategies.
-
Recognize emerging players with potentially strong product portfolio and create
effective counter-strategies to gain competitive advantage.
-
Find and recognize significant and varied types of therapeutics under development
for Acute Lymphocytic Leukemia (Oncology).
-
Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of leading
companies.
-
Plan mergers and acquisitions meritoriously by identifying key players and it's
most promising pipeline therapeutics.
-
Formulate corrective measures for pipeline projects by understanding Acute
Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication
therapeutics.
-
Develop and design in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance and expand
business potential and scope.
-
Adjust the therapeutic portfolio by recognizing discontinued projects and
understand from the know-how what drove them from pipeline.
For more
information, click on the link below:
Related Reports:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing &
Communications
0124-4230204
No comments:
Post a Comment